Y. Kadono, “Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST”, Urol J, vol. 19, no. 03, pp. 202–208, Dec. 2021.